First port of call for research:
Introduction to Dr Daniel Tillett (Chief Scientific Officer) ... and responding to questions on hotcopper
- New strategy - see AGM presentation (latest presentation) and the strategy announcement
- Literature review on company website
- Combo Poster (this was presented at a French Leukemia Conference)
- His opening post:
- Now that I am a director of RAC it gives me the chance to introduce myself (Daniel Tillett) to all of you. I have established a company rep account here on HC to enable me to answer the questions about RAC and bisantrene that you have. I can’t discuss market sensitive information, but I have noticed reading through the threads here that there are many questions that I can answer.
One of my aims is to improve communication with the shareholders and keep everyone updated on what is going on as best I can. I know it is not always easy with biotech, but I do think we can always improve.
- September 2019 - Dr Daniel Tillett joins Race Board
- August 2019 - Prominent Biotech investor leads investment in RACE
The following threads explore various aspects of the RACE Oncology strategy:
Other:
- Theoretical Revenue Potential of RACE Oncology 5-path Strategy
- Probability Scoring for Investment in Pre-approval Biotechs [important]
- The Priority Review Voucher
Periodic FA Thread - RACE Oncology
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.52 |
Change
0.030(2.01%) |
Mkt cap ! $254.2M | |||
| Open | High | Low | Value | Volume |
| $1.51 | $1.53 | $1.48 | $141.7K | 94.55K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 427 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.52 | 2999 | 2 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.51 |
Change
0.030 ( 0.85 %) |
||||
| Open | High | Low | Volume | ||
| $1.52 | $1.53 | $1.48 | 13236 | ||
| Last updated 15.53pm 21/05/2024 ? | |||||
| RAC (ASX) Chart |